Emeran Mayer

Last updated
Emeran Mayer
EA Mayer.JPG
Born (1950-07-26) 26 July 1950 (age 74)
Traunstein, Germany
Scientific career
Fields Gastroenterology
Institutions David Geffen School of Medicine at UCLA
Website emeranmayer.com

Emeran Anton Mayer (born July 26, 1950 in Traunstein, Germany) is a gastroenterologist, lecturer, author, editor, neuroscientist, documentary filmmaker and a professor in the Departments of Medicine, Physiology and Psychiatry at the David Geffen School of Medicine at UCLA. He is a pioneer of medical research into brain gut interactions [1] [2]

Contents

Early years

Mayer became interested in mind–brain–body interactions in health and chronic disease as a college student at Ludwig Maximilian University in Munich, which inspired his decision to go to medical school at Ludwig Maximilian University Medical School. His interest in documentary filmmaking galvanized this fascination and resulted in his journeys to the Yanoama tribes in the Orinoco region and the Asmat people in Irian Jaya. There, he filmed and studied native healers while exploring his suspicion that the interactions between the gut and the brain transcend culture and time. [3]

Career

Mayer's research career began at the Institute of Physiology in Munich, with a dissertation on the mechanisms by which the brain affects coronary blood flow in the heart during psychological stress. After moving to the US, he completed his specialty training as a gastroenterologist at UCLA and from then on focused his work on basic, translational, and clinical aspects of brain gut interactions. He has 40 years of experience studying clinical and neurobiological aspects of how the digestive and nervous systems interact in health and disease. [4] In the United States, Mayer's research has continuously been funded by federal grants from National Institutes of Health (NIH) grants. [5]

Mayer is a Distinguished Research Professor and the Executive Director of the Oppenheimer Family Center for Neurobiology of Stress, and Co-director of the CURE: Digestive Diseases Research Center at UCLA. He has published more than 370 scientific papers (h-index 115), and co edited 3 scientific books. He is the recipient of the 2016 David McLean award from the American Psychosomatic Society and the 2017 Ismar Boas Medal from the German Society of Gastroenterology and Metabolic Disease. As one of the pioneers and leading researchers in the role of mind-brain-body interactions in health and chronic disease, his scientific contributions to U.S. national and international communities in the broad area of basic and translational enteric neurobiology with wide-ranging applications in clinical GI diseases and disorders is unparalleled. By incorporating microbiome science into his longstanding interest in brain gut interactions, he has been studying the role of the gut microbiome in influencing brain structure and function, as he explained on National Public Radio. Dr. Mayer spoke at UCLA TEDx on The Mysterious Origins of Gut Feelings.

In addition to his longstanding research into the pathophysiology of irritable bowel syndrome, Mayer has researched Alzheimer's disease, Parkinson's disease, food addiction, obesity, ulcerative colitis, and Crohn's disease. His research efforts into these brain gut diseases have been closely linked to his strong belief in the concept of One Health, which closely links individual health, with health of the microbiome in our gut and in the soil, health of the plants and the planet. Mayer has a longstanding interest in ancient healing traditions and affords them a level of respect rarely found in Western medicine. He has personally practiced different mind based strategies, including Zen meditation, Ericksonian hypnosis, and autogenic training and his approach to patients is based on an integrative medicine concept of the close bidirectional interactions between mind, brain, body and the environment.

Books

Movies

Personal life

Mayer lives in Los Angeles, California. He is married to Minou Mayer and has one son, E. Dylan Mayer.

Related Research Articles

<span class="mw-page-title-main">Constipation</span> Infrequent or difficult bowel movements

Constipation is a bowel dysfunction that makes bowel movements infrequent or hard to pass. The stool is often hard and dry. Other symptoms may include abdominal pain, bloating, and feeling as if one has not completely passed the bowel movement. Complications from constipation may include hemorrhoids, anal fissure or fecal impaction. The normal frequency of bowel movements in adults is between three per day and three per week. Babies often have three to four bowel movements per day while young children typically have two to three per day.

<span class="mw-page-title-main">Irritable bowel syndrome</span> Functional gastrointestinal disorder

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by a group of symptoms that commonly include abdominal pain, abdominal bloating and changes in the consistency of bowel movements. These symptoms may occur over a long time, sometimes for years. IBS can negatively affect quality of life and may result in missed school or work or reduced productivity at work. Disorders such as anxiety, major depression, and chronic fatigue syndrome are common among people with IBS.

Functional abdominal pain syndrome (FAPS), chronic functional abdominal pain (CFAP), or centrally mediated abdominal pain syndrome (CMAP) is a pain syndrome of the abdomen, that has been present for at least six months, is not well connected to gastrointestinal function, and is accompanied by some loss of everyday activities. The discomfort is persistent, near-constant, or regularly reoccurring. The absence of symptom association with food intake or defecation distinguishes functional abdominal pain syndrome from other functional gastrointestinal illnesses, such as irritable bowel syndrome (IBS) and functional dyspepsia.

<span class="mw-page-title-main">Inflammatory bowel disease</span> Medical condition

Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon and small intestine, with Crohn's disease and ulcerative colitis (UC) being the principal types. Crohn's disease affects the small intestine and large intestine, as well as the mouth, esophagus, stomach and the anus, whereas UC primarily affects the colon and the rectum.

Functional gastrointestinal disorders (FGID), also known as disorders of gut–brain interaction, include a number of separate idiopathic disorders which affect different parts of the gastrointestinal tract and involve visceral hypersensitivity and motility disturbances.

Functional constipation, also known as chronic idiopathic constipation (CIC), is defined by less than three bowel movements per week, hard stools, severe straining, the sensation of anorectal blockage, the feeling of incomplete evacuation, and the need for manual maneuvers during feces, without organic abnormalities. Many illnesses, including endocrine, metabolic, neurological, mental, and gastrointestinal obstructions, can cause constipation as a secondary symptom. When there is no such cause, functional constipation is diagnosed.

<span class="mw-page-title-main">Small intestinal bacterial overgrowth</span> Medical condition

Small intestinal bacterial overgrowth (SIBO), also termed bacterial overgrowth, or small bowel bacterial overgrowth syndrome (SBBOS), is a disorder of excessive bacterial growth in the small intestine. Unlike the colon, which is rich with bacteria, the small bowel usually has fewer than 100,000 organisms per millilitre. Patients with bacterial overgrowth typically develop symptoms which may include nausea, bloating, vomiting, diarrhea, malnutrition, weight loss, and malabsorption by various mechanisms.

Intestinal permeability is a term describing the control of material passing from inside the gastrointestinal tract through the cells lining the gut wall, into the rest of the body. The intestine normally exhibits some permeability, which allows nutrients to pass through the gut, while also maintaining a barrier function to keep potentially harmful substances from leaving the intestine and migrating to the body more widely. In a healthy human intestine, small particles can migrate through tight junction claudin pore pathways, and particles up to 10–15 Å can transit through the paracellular space uptake route. There is some evidence abnormally increased intestinal permeability may play a role in some chronic diseases and inflammatory conditions. The most well understood condition with observed increased intestinal permeability is celiac disease.

<span class="mw-page-title-main">Pelvic pain</span> Medical condition

Pelvic pain is pain in the area of the pelvis. Acute pain is more common than chronic pain. If the pain lasts for more than six months, it is deemed to be chronic pelvic pain. It can affect both the male and female pelvis.

<span class="mw-page-title-main">Sir William Arbuthnot Lane, 1st Baronet</span> British surgeon (1856–1943)

Sir William Arbuthnot Lane, 1st Baronet, CB, FRCS was a British surgeon and physician. He mastered orthopaedic, abdominal, and ear, nose and throat surgery, while designing new surgical instruments toward maximal asepsis. He thus introduced the "no-touch technique", and some of his designed instruments remain in use.

The Rome process and Rome criteria are an international effort to create scientific data to help in the diagnosis and treatment of functional gastrointestinal disorders, such as irritable bowel syndrome, functional dyspepsia and rumination syndrome. The Rome diagnostic criteria are set forth by Rome Foundation, a not for profit 501(c)(3) organization based in Raleigh, North Carolina, United States.

Dysbiosis is characterized by a disruption to the microbiome resulting in an imbalance in the microbiota, changes in their functional composition and metabolic activities, or a shift in their local distribution. For example, a part of the human microbiota such as the skin flora, gut flora, or vaginal flora, can become deranged (unbalanced), when normally dominating species become underrepresented and species that normally are outcompeted or contained increase to fill the void. Similar to the human gut microbiome, diverse microbes colonize the plant rhizosphere, and dysbiosis in the rhizosphere, can negatively impact plant health. Dysbiosis is most commonly reported as a condition in the gastrointestinal tract or plant rhizosphere.

Alverine is a drug used for functional gastrointestinal disorders. Alverine is a smooth muscle relaxant. Smooth muscle is a type of muscle that is not under voluntary control; it is the muscle present in places such as the gut and uterus.

Functional disorders are a group of recognisable medical conditions which are due to changes to the functioning of the systems of the body rather than due to a disease affecting the structure of the body.

Bile acid malabsorption (BAM), known also as bile acid diarrhea, is a cause of several gut-related problems, the main one being chronic diarrhea. It has also been called bile acid-induced diarrhea, cholerheic or choleretic enteropathy, bile salt diarrhea or bile salt malabsorption. It can result from malabsorption secondary to gastrointestinal disease, or be a primary disorder, associated with excessive bile acid production. Treatment with bile acid sequestrants is often effective. Depending on the severity of symptoms, it may be recognised as a disability in the United Kingdom under the Equality Act 2010.

<span class="mw-page-title-main">Gut–brain axis</span> Biochemical signaling between the gastrointestinal tract and the central nervous system

The gut–brain axis is the two-way biochemical signaling that takes place between the gastrointestinal tract and the central nervous system (CNS). The term "microbiota–gut–brain axis" highlights the role of gut microbiota in these biochemical signaling. Broadly defined, the gut–brain axis includes the central nervous system, neuroendocrine system, neuroimmune systems, the hypothalamic–pituitary–adrenal axis, sympathetic and parasympathetic arms of the autonomic nervous system, the enteric nervous system, vagus nerve, and the gut microbiota.

Bacteriotherapy is the purposeful use of bacteria or their products in treating an illness. Forms of bacteriotherapy include the use of probiotics, microorganisms that provide health benefits when consumed; fecal matter transplants (FMT) /intestinal microbiota transplant (IMT), the transfer of gut microorganisms from the fecal matter of healthy donors to recipient patients to restore microbiota; or synbiotics which combine prebiotics, indigestible ingredients that promote growth of beneficial microorganisms, and probiotics. Through these methods, the gut microbiota, the community of 300-500 microorganism species that live in the digestive tract of animals aiding in digestion, energy storage, immune function and protection against pathogens, can be recolonized with favorable bacteria, which in turn has therapeutic effects.

Bifidobacterium breve is a bacterial species of the genus Bifidobacterium which has probiotic properties. Bifidobacteria are a type of bacteria that live symbiotically in the intestines of humans. They have been used to treat a number of conditions including constipation, diarrhea, irritable bowel syndrome and even the cold and flu. Some of these uses have been backed up by scientific research, but others have not. B. breve is a gram positive, anaerobic, rod shaped organism that is non motile and forms branches with its neighbors.

Serum-derived bovine immunoglobulin/protein isolate (SBI) is a medical food product derived from bovine serum obtained from adult cows in the United States. It is sold under the name EnteraGam.

The gut–memory connection is the relation between the gastrointestinal tract and memory performance. The phenomenon of the gut–memory connection is based on and part of the idea of the gut-brain axis, a complex communication network, linking the central nervous system to the gut. The gut-brain axis first gained significant momentum in research and formal recognition in the 20th century with advancements in neuroscience and gastroenterology. The idea of a connection between the gut and emotion has been hinted at in various ancient traditions and medical practices for centuries.

References

  1. Mayer EA, Baldi JP. Can regulatory peptides be regarded as words of a biological language. Am J Physiol Gastrointest Liver Physiol 261:G171-G184, 1991
  2. Mayer EA. Clinical Perspectives: Irritable bowel syndrome. NEJM 358:1692-9, 2008
  3. Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol 6:306-14, 2009
  4. Mayer EA. Gut feelings: the emerging biology of gut-brain communication. Nat Rev Neurosci 12:453-66, 2011
  5. Jarcho J, Mayer EA, Jian K, London ED. Pain, affective symptoms, and cognitive deficits in patients with cerebral dopamine dysfunction. Pain 2012 Feb. 29 [Epub ahead of print]